Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20582975 | 0.83 | RAB9A (0.46) | DHODHGPR119MPOBRD4ALDH1A1 | |
| SCHEMBL287686 | 0.81 | ALDH1A1 (0.45) | DRD2ALDH1A1NOTUMDRD4 | |
| SCHEMBL1466633 | 0.79 | DHODH (0.56) | DHODHGPR119DRD2CHRM4HTR7 | |
| SCHEMBL8200750 | 0.77 | NOTUM (0.64) | DHODHGPR119DRD2BRD4ALDH1A1 | |
| SCHEMBL3899182 | 0.77 | ESR2 (0.61) | DHODHGPR119DRD2CHRM4HTR7 | |
| SCHEMBL13691905 | 0.77 | DHODH (0.53) | DHODHGPR119MPOBRD4ALDH1A1 | |
| SCHEMBL760643 | 0.76 | ABHD6 (0.63) | DHODHGPR119DRD2CHRM4HTR7 | |
| SCHEMBL8269763 | 0.76 | GPR119 (0.47) | DHODHGPR119DRD2CHRM4HTR7 | |
| SCHEMBL1058537 | 0.76 | NR1H2 (0.62) | DHODHGPR119DRD2CHRM4HTR7 | |
| SCHEMBL2005945 | 0.76 | GPR119 (0.47) | DHODHGPR119DRD2CHRM4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | DHODH 3930/4885GPR119 1/4885DRD2 1614/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | DHODH 3699/4885GPR119 1/4885DRD2 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.